Imsidolimab

Name: Imsidolimab in Generalized pustular psoriasis: Generic, brand name and therapeutic class of product
Published: 2026-09-14T15:39:06-04:00

Generalized pustular psoriasis

Manufacturer: Vanda Pharmaceuticals
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

3 evidence topics · 3 sources

Manufacturer: Vanda Pharmaceuticals

“Vanda will receive an exclusive global license to develop, manufacture and commercialize imsidolimab.” (opens the source at this quote in a new tab)

Product names in the development update

“Quimilza™ (imsidolimab)” (opens the source at this quote in a new tab)

Drug class and molecular description

“Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling” (opens the source at this quote in a new tab)